NCT06328049View on ClinicalTrials.gov

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

February 10, 2025

Study Completion Date

August 10, 2025

Conditions
NSCLC
Interventions
DRUG

Trilaciclib Injection

Patients with lung adenocarcinoma were given Trilaciclib combined with pemetrexed and carboplatin, Q3W; For patients with lung squamous cell carcinoma,Trilaciclib combined with paclitaxel/albumin-bound paclitaxel and carboplatin, Q3W. From cycle 2 onwards, patients chose whether to use trasylol with chemotherapy.

Trial Locations (1)

225400

RECRUITING

Taixing People's Hospital, Taishing

All Listed Sponsors
lead

Taixing People's Hospital

OTHER